Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 8/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31756504 | 1.00 | AHCY (0.64) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL14520301 | 1.00 | AHCY (0.64) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL31756651 | 1.00 | AHCY (0.64) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL26811312 | 1.00 | AHCY (0.64) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL26811459 | 0.90 | PI4KA (0.55) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL26811445 | 0.90 | PI4KA (0.55) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL31756696 | 0.90 | PI4KA (0.55) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL16424887 | 0.89 | AHCY (0.60) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL5319686 | 0.87 | PI4KA (0.47) | AHCYADORA2BPI4K2API4KAPI4K2B | |
| SCHEMBL17889809 | 0.87 | PI4KA (0.47) | AHCYADORA2BPI4K2API4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230061-A2 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | AHCY 2783/4885ADORA2B 38/4885PI4K2A 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.